Use of carrier peptides for linking B epitope or semiantigen and immunogen containing carrier peptide in medicine and immunology
A peptide immunogen and carrier peptide technology, applied in immunology, pharmacy and medical related fields, can solve the problem of promoting B cell epitope or peptide hapten immunogenicity, to improve immunogenicity, increase CD4+, reduce CD8 +T cell effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0037] Example 1: A class of structured carrier peptides containing T helper epitopes (Th epitopes) IA-2(5)-P2-1,2-IA-2(5)-P2-1,3-IA -2(5)-P2-1, 4-IA-2(5)-P2-1, IA-2(5)-6-P2-1, etc. (abbreviated as IP, 2-IP, 3-IP, 4 -IP, I6P, etc.) preparation.
[0038] A linear B cell epitope IA2(5) peptide segment of IA-2 is selected, the amino acid sequence 1 is shown in SEQ ID NO.1, the Th2 epitope P2 peptide segment at the C-terminal of P277, the amino acid sequence 2 is shown in SEQ ID NO.2, P2 The modified peptide (position 448 or position 455 is any amino acid residue, see SEQ ID NO. 2 for the amino acid sequence). When the 455th position is the amino acid residue A, it is named PA, and when the 448th position is the amino acid residue A, it is named AP.
[0039] Using a variety of analysis software and screening, analysis, identification and modification of multiple STZ diabetic model mouse experiments, it was determined that the two epitopes were linked by flexible peptides, and th...
Embodiment 2
[0040] Example 2: Preparation of B cell epitopes or synthetic peptide hapten B.
[0041]Using a variety of B cell antigen epitope analysis software and online analysis tools, based on a single parameter, combined with secondary structure prediction and spatial structure characteristics, respectively, from a target antigen protein (such as: human DPP4 or human XOD or human uric acid transporter protein). 1 or more than 100 epitopes of human acetylcholinesterase) to select multiple dominant B cell antigen epitopes or peptide hapten B, by combining with carrier peptide IP, 2-IP, 3-IP, 4-IP, 6-IP IP and I6P are linked with flexible peptides, and the B cell epitope or synthetic peptide hapten B with high immunogenicity is obtained through the process of screening, re-engineering and re-screening in immunization animal experiments.
Embodiment 2-1
[0042] Example 2-1 When B is the dominant B cell epitope of human dipeptidyl peptidase 4 (DPP4), the preparation method is to select D41, D42, D43, D44- ---- etc. Multiple predicted dominant B cell epitopes or peptide hapten B, by combining with carrier peptides IP, 2-IP, 3-IP, 4-IP, 6-IP and I6P etc. N-terminal to flexible The peptides are linked to form peptide immunogens, and the highly immunogenic B cell antigen epitopes or peptide haptens D41, D42, D43, etc. are obtained through screening of immunized animals. D41 is a polypeptide sequence 88VFLENSTFDE97 of DPP4, with a total of 10 amino acid residues.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com